Medicine counterfeiting as a global health problem
Keywords:
pharmaceutical companies, public health, global health, counterfeit medicinesAbstract
Introduction: Counterfeit and falsified medicines are one of the most important global health challenges, endangering patients’ lives, undermining the sustainability of healthcare systems and creating serious risks to public health. This study aims to provide an in-depth analysis of the global scale, causes and consequences of counterfeit and falsified medicines. Methodology: Theoretical material from relevant literature was processed and analyzed. Results: The results of the study highlight the negative impact of counterfeit medicines on public health and the economy, which is manifested in the development of drug resistance, treatment failure and loss of patient trust in healthcare systems. The paper demonstrates the importance of effective prevention and detection strategies, including the introduction of technological innovations and regulatory measures, raising public awareness and strengthening international cooperation. The study highlights the need for a coordinated effort involving international organizations, governments and the private sector to reduce the spread of counterfeit medicines and ensure patient safety. Conclusion: The foundation for a reliable global pharmaceutical supply chain is the continuous development of technologies, strengthened regulatory frameworks, increased public awareness and strong international cooperation. Achieving this goal requires a coordinated and united effort from all stakeholders — governments, international organizations, pharmaceutical companies, healthcare professionals and consumers.
References
• African Medicines Regulatory Harmonization. (2021). Overview of AMRH Initiative. Retrieved from https://www.nepad.org/agency/african-medicines-regulatory-harmonization-amrh
• Andrew J, Deva Priya Isravel, K. Martin Sagayam, Bharat Bhushan, Yuichi Sei, Jennifer Eunice (2023). Blockchain for healthcare systems: Architecture, security challenges, trends and future directions. *Journal of Network and Computer Applications*, 215. https://doi.org/10.1016/j.jnca.2023.103633
• Balfour, H. (2022). The latest on pharmaceutical counterfeiting. (2022, June 27). *European Pharmaceutical Review*. Retrieved from https://www.europeanpharmaceuticalreview.com/article/170913/the-latest-on-pharmaceutical-counterfeiting/?form=MG0AV3
• Baldini, G., Fovino, I., Satta, R., Tsois, A., & Checchi, E. (2015). Survey of techniques for the fight against counterfeit goods and Intellectual Property Rights (IPR) infringement 2015 EUR 27688 EN. https://doi.org/10.2788/97231
• Bate, R., Jin, G. Z., & Mathur, A. (2019). Falsified or substandard? Assessing price and non-price signals of drug quality. *Journal of Health Economics*, 67, 102224. Retrieved from https://www.sciencedirect.com/science/article/pii/S016762961830692X
• Blackstone, E. A., Fuhr, J. P., Jr, & Pociask, S. (2014). The health and economic effects of counterfeit drugs. *American Health & Drug Benefits*, 7(4), 216–224.
• El-Dahiyat, F., Fahelelbom, K. M. S., Jairoun, A. A., & Al-Hemyari, S. S. (2021). Combatting Substandard and Falsified Medicines: Public Awareness and Identification of Counterfeit Medications. *Frontiers in Public Health*, 9. https://doi.org/10.3389/fpubh.2021.754279
• European Medicines Agency (2016) Falsified medicines: Overview. European Medicines Agency. Retrieved from https://www.ema.europa.eu/en/human-regulatory-overview/public-health-threats/falsified-medicines-overview#:~:text=Falsified%20medicines%20are%20fake%20medicines%20that%20are%20designed%20to%20mimic,or%20that%20infringe%20trademark%20law
• Global Surveillance and Monitoring System for substandard and falsified medical products. (2024). World Health Organization. Retrieved from https://www.who.int/publications/i/item/9789240097513
• Karunamoorthi, K. (2014). The counterfeit anti-malarial is a crime against humanity: a systematic review of the scientific evidence. *Malaria Journal*, 13, 209. https://doi.org/10.1186/1475-2875-13-209
• Khurelbat, D., Dorj, G., Sunderland, B., Sanjjav, T., Bayarsaikhan, E., Damdinjav, D., Dorj, G., Jigjidsuren, A., Lkhagvasuren, O., & Erdenetsetseg, B. (2020). A cross-sectional analysis of falsified, counterfeit and substandard medicines in a low-middle income country. *BMC Public Health*, 20(1), 743. https://doi.org/10.1186/s12889-020-08897-x
• Knox, R. (2012). FDA Warns About Fake Avastin In U.S. *NPR*. Retrieved from https://www.npr.org/sections/health-shots/2012/02/15/146929475/fda-warns-about-fake-avastin-in-us
• Kovacs, S., Hawes, S. E., Maley, S. N., Mosites, E., Wong, L., & Stergachis, A. (2014). Technologies for detecting falsified and substandard drugs in low and middle-income countries. *PloS One*, 9(3), e90601. https://doi.org/10.1371/journal.pone.0090601
• Liu, H., Zhang, Z., & Linhardt, R. J. (2009). Lessons learned from the contamination of heparin. *Natural Product Reports*, 26(3), 313–321. https://doi.org/10.1039/b819896a
• Mackey, T. K., & Liang, B. A. (2011). The global counterfeit drug trade: patient safety and public health risks. *Journal of Pharmaceutical Sciences*, 100(11), 4571–4579. https://doi.org/10.1002/jps.22679
• Ofori-Parku, S. S. (2022). Fighting the global counterfeit medicines challenge: A consumer-facing communication strategy in the US is an imperative. *Journal of Global Health*, 12, 03018. https://doi.org/10.7189/jogh.12.03018
• Pathak, R., Gaur, V., Sankrityayan, H., & Gogtay, J. (2023). Tackling Counterfeit Drugs: The Challenges and Possibilities. *Pharmaceutical Medicine*, 37(4), 281–290. https://doi.org/10.1007/s40290-023-00468-w
• Sallam, K., Mohamed, M., & Wagdy, A. (2023). Internet of Things (IoT) in Supply Chain Management: Challenges, Opportunities, and Best Practices. *Sustainable Machine Intelligence Journal*, 2. https://doi.org/10.61185/SMIJ.2023.22103
• Sweileh, W. M. (2021). Substandard and falsified medical products: bibliometric analysis and mapping of scientific research. *Global Health*, 17, 114. https://doi.org/10.1186/s12992-021-00766-5
